The Efficacy and Prevalence of Montelukast Therapy in Cough-Variant Asthma Patients in Al-Kindy Teaching Hospital

  • Saba Jasim Hamdan Department of Pharmacology, Al-Kindy College of Medicine, University of Baghdad, Baghdad, Iraq
Keywords: Cough Variant Asthma, Montelukast


BACKGROUND: Cough-variant asthma (CVA) is a type of asthma in which the main symptom is a dry, non-productive cough.

OBJECTIVE: The objective of the study was to evaluate the therapeutic effect of Montelukast in CVA and to investigate the prevalence of Montelukast in CVA.

METHODS: A cross-sectional study was conducted on 30 patients with chronic cough at least 8 weeks using Montelukast at Al-Kindy Hospital over the period of January 2018‒March 2018. An interview using questionnaire was used to collect the data that were specifically prepared to meet the objective of study including age, sex, associated disease, exacerbation factors, and classical therapy.

RESULTS: There was a reduction of the symptoms associated with CVA after treatment with Montelukast. The prevalence of exacerbation factors was as follows: Dust (73.3%) of patients, food (36.7%), exercise (60%), psychological (56.7%), smoking (30%), and others (perfume and cold weather) (26.7%). The usage of Montelukast in this study was 73.3% (22 patients). Patients using Montelukast have shown improvement of symptoms as follows: Chest pain was relieved from 57.1% of patients, exhaustion (58.3%), vomiting (76.5%), sleep disturbance (54.5%), affecting daily life in 57.1%, and syncope 66.7%.

CONCLUSION: The prevalence of Montelukast administration to the patients with chronic cough in our study was found to be more than 70% of the 30 total patients. Montelukast usage leads to reduction in the frequency of chronic cough and the symptoms associated with it.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Corrao WM. Pearls and pitfalls in the diagnosis of cough variant asthma. Allergy Asthma Proc. 2018;39(6):466-7. https://doi. org/10.2500/aap.2018.39.4168 PMid:30401324

Niimi A. Cough and asthma. Curr Respir Med Rev. 2011;7(1):47-54. PMid:22081767

Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18(5):693-704. PMid:22561833

Mason R, Broaddus VC, Martin T, King T, Schraufnagel D, Murray J, et al. Murray and Nadel’s Textbook of Respiratory Medicine. Philadelphia, PA: Saunders; 2010. https://doi. org/10.1016/b978-1-4160-4710-0.00101-2

Hamdan SJ, Al-Attar Z, Hashim I. Prevalence of montelukast use as an add-on therapy among Iraqi asthmatics on treatment attending Al-Kindy teaching hospital and Al-Zahraa center of asthma and allergy. Open Access Maced J Med Sci. 2019;7(14):2246-50. PMid:31592270

Zubairi AB, Salahuddin N, Khawaja A, Awan S, Shah AA, Haque AS, et al. A randomized, double-blind, placebo-controlled trial of oral montelukast in acute asthma exacerbation. BMC Pulm Med. 2013;13:20. PMid:23537391

Hirshon JM, Weiss SR, LoCasale R, Levine E, Blaisdell CJ. Looking beyond urban/rural differences: Emergency department utilization by asthmatic children. J Asthma. 2006;43(4):301-6. PMid:16809244

Sole D, Cassol VE, Silva AR, Teche SP, Rizzato TM, Bandim LC, et al. Prevalence of symptoms of asthma, rhinitis, and atopic eczema among adolescents living in urban and rural areas in different regions of Brazil. Allergol Immunopathol (Madr). 2007;35(6):248-53. PMid:18047816

Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. New Engl J Med. 1998;339(3):147-52. PMid:9664090

Stapleton M, Howard-Thompson A, George C, Hoover RM, Self TH. Smoking and asthma. J Am Board Fam Med. 2011;24(3):313-22. PMid:21551404

Wright MF, Balfour-Lynn IM. Habit-tic cough: Presentation and outcome with simple reassurance. Pediatr Pulmonol. 2018;53(4):512-6. PMid:29363880

Al-Hamdani FY. Comparative clinical evaluation of ketotifen and montelukast sodium in asthmatic Iraqi patients. Saudi Pharm J. 2010;18(4):245-9. PMid:23960734

Canadian Agency for Drugs and Technologies in Health. Montelukast for Sleep Apnea: A Review of the Clinical Effectiveness, Cost Effectiveness, and Guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2014.

Beckman TJ. Syncope in an adult with uncontrolled asthma. South Med J. 2002;95(3):369-70. PMid:11902710

Ojo OT, Ozoh O. Cough Syncope, an Unusual Presentation of Asthma in Adults. B45. Obstructive Lung Disease: Interesting Cases. American Thoracic Society International Conference Abstracts. New York: American Thoracic Society; 2016. p. A3587.

French CL, Irwin RS, Curley FJ, Krikorian CJ. Impact of chronic cough on quality of life. Arch Intern Med. 1998;158(15):1657-61. PMid:9701100

Mincheva RK, Kralimarkova TZ, Rasheva M, Dimitrov Z, Nedeva D, Staevska M, et al. A real-life observational pilot study to evaluate the effects of two-week treatment with montelukast in patients with chronic cough. Cough. 2014;10(1):2. https://doi. org/10.1186/1745-9974-10-2 PMid:24649919

How to Cite
Hamdan SJ. The Efficacy and Prevalence of Montelukast Therapy in Cough-Variant Asthma Patients in Al-Kindy Teaching Hospital. Open Access Maced J Med Sci [Internet]. 2020Apr.25 [cited 2020Oct.31];8(B):156-9. Available from: